These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 26595521

  • 41. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
    Gloesenkamp C, Nitzsche B, Lim AR, Normant E, Vosburgh E, Schrader M, Ocker M, Scherübl H, Höpfner M.
    Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
    [Abstract] [Full Text] [Related]

  • 42. FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.
    Künstlinger H, Fassunke J, Schildhaus HU, Brors B, Heydt C, Ihle MA, Mechtersheimer G, Wardelmann E, Büttner R, Merkelbach-Bruse S.
    Oncotarget; 2015 Aug 21; 6(24):20215-30. PubMed ID: 26036639
    [Abstract] [Full Text] [Related]

  • 43. Combinatorial Inhibition of mTORC2 and Hsp90 Leads to a Distinctly Effective Therapeutic Strategy in Malignant Pheochromocytoma.
    Zhang X, Gao F, Zhong S.
    Curr Cancer Drug Targets; 2019 Aug 21; 19(9):698-706. PubMed ID: 30727894
    [Abstract] [Full Text] [Related]

  • 44. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.
    Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH, Goettl VM, Zhang X, Jarjoura D, Raymond CA, West DA, Croce CM, Byrd JC, Johnson AJ.
    Blood; 2010 Jul 08; 116(1):45-53. PubMed ID: 20351313
    [Abstract] [Full Text] [Related]

  • 45. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.
    Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, Cook RS.
    J Clin Invest; 2013 Oct 08; 123(10):4329-43. PubMed ID: 23999432
    [Abstract] [Full Text] [Related]

  • 46. The effects of Hsp90 expression alteration on spinal metastases of breast carcinoma.
    Yan W, Xiao J, Liu T, Huang W, Yang X, Wu Z, Huang Q, Qian M.
    Tumour Biol; 2013 Jun 08; 34(3):1391-7. PubMed ID: 23456764
    [Abstract] [Full Text] [Related]

  • 47. ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition.
    Dote H, Cerna D, Burgan WE, Camphausen K, Tofilon PJ.
    Cancer Res; 2005 Aug 01; 65(15):6967-75. PubMed ID: 16061682
    [Abstract] [Full Text] [Related]

  • 48. Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option.
    Willems SM, Schrage YM, Bruijn IH, Szuhai K, Hogendoorn PC, Bovée JV.
    Mol Cancer; 2010 Sep 23; 9():257. PubMed ID: 20863376
    [Abstract] [Full Text] [Related]

  • 49. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
    Schwock J, Dhani N, Cao MP, Zheng J, Clarkson R, Radulovich N, Navab R, Horn LC, Hedley DW.
    Cancer Res; 2009 Jun 01; 69(11):4750-9. PubMed ID: 19458065
    [Abstract] [Full Text] [Related]

  • 50. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.
    Liles JS, Arnoletti JP, Tzeng CW, Howard JH, Kossenkov AV, Kulesza P, Heslin MJ, Frolov A.
    Cancer Biol Ther; 2010 Sep 15; 10(6):555-63. PubMed ID: 20647770
    [Abstract] [Full Text] [Related]

  • 51. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
    Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ.
    Clin Cancer Res; 2004 Dec 01; 10(23):8077-84. PubMed ID: 15585643
    [Abstract] [Full Text] [Related]

  • 52. Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses.
    Svec D, Dolatabadi S, Thomsen C, Cordes N, Shannon M, Fitzpatrick P, Landberg G, Åman P, Ståhlberg A.
    Lab Invest; 2018 Jul 01; 98(7):957-967. PubMed ID: 29588491
    [Abstract] [Full Text] [Related]

  • 53. Radiation sensitivity assay with a panel of patient-derived spheroids of small cell carcinoma of the cervix.
    Nakajima A, Endo H, Okuyama H, Kiyohara Y, Kimura T, Kamiura S, Hiraoka M, Inoue M.
    Int J Cancer; 2015 Jun 15; 136(12):2949-60. PubMed ID: 25408479
    [Abstract] [Full Text] [Related]

  • 54. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
    Wang J, Li Z, Lin Z, Zhao B, Wang Y, Peng R, Wang M, Lu C, Shi G, Shen Y.
    Cancer Lett; 2015 Jun 28; 362(1):83-96. PubMed ID: 25813406
    [Abstract] [Full Text] [Related]

  • 55. Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.
    Zhang H, Yang YC, Zhang L, Fan J, Chung D, Choi D, Grecko R, Timony G, Karjian P, Boehm M, Burrows F.
    Int J Cancer; 2007 Feb 15; 120(4):918-26. PubMed ID: 17131314
    [Abstract] [Full Text] [Related]

  • 56. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.
    O'Malley KJ, Langmann G, Ai J, Ramos-Garcia R, Vessella RL, Wang Z.
    Prostate; 2012 Jul 01; 72(10):1117-23. PubMed ID: 22161776
    [Abstract] [Full Text] [Related]

  • 57. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells.
    Ueno Y, Sakurai H, Tsunoda S, Choo MK, Matsuo M, Koizumi K, Saiki I.
    Int J Cancer; 2008 Jul 15; 123(2):340-347. PubMed ID: 18398842
    [Abstract] [Full Text] [Related]

  • 58. Requirement for YAP1 signaling in myxoid liposarcoma.
    Trautmann M, Cheng YY, Jensen P, Azoitei N, Brunner I, Hüllein J, Slabicki M, Isfort I, Cyra M, Berthold R, Wardelmann E, Huss S, Altvater B, Rossig C, Hafner S, Simmet T, Ståhlberg A, Åman P, Zenz T, Lange U, Kindler T, Scholl C, Hartmann W, Fröhling S.
    EMBO Mol Med; 2019 May 15; 11(5):. PubMed ID: 30898787
    [Abstract] [Full Text] [Related]

  • 59. Assessing the impact of HER2 status on the antitumor activity of an HSP90 inhibitor in human tumor xenograft mice using pharmacokinetic-pharmacodynamic modeling.
    Saitoh R, Nagayasu M, Shibahara N, Ono N, Suda A, Kato M, Ishigai M.
    Drug Metab Pharmacokinet; 2014 May 15; 29(2):185-91. PubMed ID: 24126359
    [Abstract] [Full Text] [Related]

  • 60. Identification of genes differentially expressed in TLS-CHOP carrying myxoid liposarcomas.
    Thelin-Järnum S, Lassen C, Panagopoulos I, Mandahl N, Aman P.
    Int J Cancer; 1999 Sep 24; 83(1):30-3. PubMed ID: 10449603
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.